When serial entrepreneur Clarissa Desjardins founded Congruence Therapeutics, her goal was to solve a class of diseases caused by protein misfolding that has long resisted traditional drug discovery approaches. Rather than targeting downstream symptoms, Congruence focuses on the root biophysical problem: designing small molecules that bind directly to misfolded proteins and restore them to functional conformations.
“Congruence is a computationally enabled drug discovery company developing small molecule drugs that can bind and correct misfolded proteins,” says Desjardins. “These proteins are often involved in rare but very serious diseases, where there are currently no effective therapies.”
While many of these conditions are classified as rare, they represent substantial clinical and commercial opportunities. Congruence’s initial programs target genetic obesity, GBA-driven Parkinson’s disease, and alpha-1 antitrypsin deficiency — diseases with severe consequences for patients and well-established precedents for premium reimbursement when effective therapies emerge. “For example, drugs which have transformed the lives of patients with cystic fibrosis, addressing populations of 100,000 patients or less have translated into several billion-dollar market opportunities,” Desjardins notes.
A platform built on computational insight
Congruence’s approach is powered by a proprietary computational platform that integrates biophysics, molecular simulations, and machine learning to understand how proteins fold, misfold, and fluctuate between conformations. By modeling these dynamics in silico, the company can identify druggable pockets and rationally design small molecules capable of stabilizing functional protein states, even for targets long considered undruggable.
This platform-first strategy enables Congruence to move faster and with greater precision than traditional screening-based discovery models, while also generating highly differentiated chemical matter. The result is a pipeline of first-in-class pharmacological correctors aimed at diseases where patients currently have few if any options.
A trusted partner from day one
From the outset, working together was a key foundational principle that led to the co-founding of the company with Amplitude Ventures. The relationship was rooted in long-standing trust. Desjardins had known Amplitude’s founders and Partners for decades, having previously served on boards with them. Desjardins had also worked closely with Amplitude Co-Founder and Partner, Jean-François Pariseau, at her previous company, Clementia Pharmaceuticals, which she ultimately sold to Ipsen.
That history really matters. At Clementia, Pariseau had supported the company through critical inflection points — from in-licensing a key asset to navigating multiple financing rounds and an IPO — while consistently anchoring decisions in long-term value creation. “He always took a stand on principle in the key decisions that needed to be made,” says Desjardins. “That’s what made him a trusted partner, and that’s why I was excited to work with him again at Amplitude.”
“Amplitude was the first to raise their hand when I started Congruence,” she notes. “They also truly understand what we’re doing and have a great network that we’ve been able to tap into.”
Conviction capital and strategic support
Amplitude’s early backing helped Congruence move decisively from concept to execution. In 2022, Amplitude led the company’s $50 million Series A financing, supporting the expansion of its platform and the advancement of its initial programs toward the clinic.
Beyond capital, Amplitude has played an active strategic role, providing guidance informed by deep experience in precision medicine, rare disease development, and company building. That support helped Congruence maintain focus on high-impact indications, build the right team, and pursue a disciplined approach to pipeline development in a challenging biotech environment.
Building for long-term impact
Today, Congruence is advancing a growing pipeline of programs designed to correct protein misfolding at its source, a strategy that could redefine how a broad range of genetic and neurodegenerative diseases are treated. The company’s ambition extends beyond individual assets to building a durable platform capable of generating multiple medicines over time.
For Desjardins, having an aligned venture partner has been critical to that mission. “Amplitude understands the science, but they also understand what it takes to build a company,” she says. “They’ve been supportive from the very beginning, and that makes a real difference when you’re tackling hard problems.”
What began as a shared conviction between long-time collaborators has evolved into a partnership anchored in trust, scientific rigor, and a commitment to patient impact. With Congruence Therapeutics, Amplitude Ventures is helping advance a new generation of precision medicines designed not just to treat diseases, but to correct them at a molecular level.
